Antioxidants for male subfertility.

Show simple item record

dc.contributor.author de Ligny, Wiep
dc.contributor.author Smits, Roos M
dc.contributor.author Mackenzie-Proctor, Rebecca
dc.contributor.author Jordan, Vanessa
dc.contributor.author Fleischer, Kathrin
dc.contributor.author de Bruin, Jan Peter
dc.contributor.author Showell, Marian G
dc.coverage.spatial England
dc.date.accessioned 2022-06-07T23:33:28Z
dc.date.available 2022-06-07T23:33:28Z
dc.date.issued 2022-05-04
dc.identifier.citation (2022). Cochrane Database of Systematic Reviews, 5(5), CD007411-.
dc.identifier.issn 1469-493X
dc.identifier.uri https://hdl.handle.net/2292/59575
dc.description.abstract <h4>Background</h4>The inability to have children affects 10% to 15% of couples worldwide. A male factor is estimated to account for up to half of the infertility cases with between 25% to 87% of male subfertility considered to be due to the effect of oxidative stress. Oral supplementation with antioxidants is thought to improve sperm quality by reducing oxidative damage. Antioxidants are widely available and inexpensive when compared to other fertility treatments, however most antioxidants are uncontrolled by regulation and the evidence for their effectiveness is uncertain. We compared the benefits and risks of different antioxidants used for male subfertility.<h4>Objectives</h4>To evaluate the effectiveness and safety of supplementary oral antioxidants in subfertile men.<h4>Search methods</h4>The Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO, AMED, and two trial registers were searched on 15 February 2021, together with reference checking and contact with experts in the field to identify additional trials.<h4>Selection criteria</h4>We included randomised controlled trials (RCTs) that compared any type, dose or combination of oral antioxidant supplement with placebo, no treatment, or treatment with another antioxidant, among subfertile men of a couple attending a reproductive clinic. We excluded studies comparing antioxidants with fertility drugs alone and studies that included men with idiopathic infertility and normal semen parameters or fertile men attending a fertility clinic because of female partner infertility.<h4>Data collection and analysis</h4>We used standard methodological procedures recommended by Cochrane. The primary review outcome was live birth. Clinical pregnancy, adverse events and sperm parameters were secondary outcomes.<h4>Main results</h4>We included 90 studies with a total population of 10,303 subfertile men, aged between 18 and 65 years, part of a couple who had been referred to a fertility clinic and some of whom were undergoing medically assisted reproduction (MAR). Investigators compared and combined 20 different oral antioxidants. The evidence was of 'low' to 'very low' certainty: the main limitation was that out of the 67 included studies in the meta-analysis only 20 studies reported clinical pregnancy, and of those 12 reported on live birth. The evidence is current up to February 2021. Live birth: antioxidants may lead to increased live birth rates (odds ratio (OR) 1.43, 95% confidence interval (CI) 1.07 to 1.91, P = 0.02, 12 RCTs, 1283 men, I<sup>2</sup> = 44%, very low-certainty evidence). Results in the studies contributing to the analysis of live birth rate suggest that if the baseline chance of live birth following placebo or no treatment is assumed to be 16%, the chance following the use of antioxidants is estimated to be between 17% and 27%. However, this result was based on only 246 live births from 1283 couples in 12 small or medium-sized studies. When studies at high risk of bias were removed from the analysis, there was no evidence of increased live birth (Peto OR 1.22, 95% CI 0.85 to 1.75, 827 men, 8 RCTs, P = 0.27, I<sup>2</sup> = 32%). Clinical pregnancy rate: antioxidants may lead to increased clinical pregnancy rates (OR 1.89, 95% CI 1.45 to 2.47, P < 0.00001, 20 RCTs, 1706 men, I<sup>2</sup> = 3%, low-certainty evidence) compared with placebo or no treatment. This suggests that, in the studies contributing to the analysis of clinical pregnancy, if the baseline chance of clinical pregnancy following placebo or no treatment is assumed to be 15%, the chance following the use of antioxidants is estimated to be between 20% and 30%. This result was based on 327 clinical pregnancies from 1706 couples in 20 small studies. Adverse events Miscarriage: only six studies reported on this outcome and the event rate was very low. No evidence of a difference in miscarriage rate was found between the antioxidant and placebo or no treatment group (OR 1.46, 95% CI 0.75 to 2.83, P = 0.27, 6 RCTs, 664 men, I<sup>2</sup> = 35%, very low-certainty evidence). The findings suggest that in a population of subfertile couples, with male factor infertility, with an expected miscarriage rate of 5%, the risk of miscarriage following the use of an antioxidant would be between 4% and 13%. Gastrointestinal: antioxidants may lead to an increase in mild gastrointestinal discomfort when compared with placebo or no treatment (OR 2.70, 95% CI 1.46 to 4.99, P = 0.002, 16 RCTs, 1355 men, I<sup>2</sup> = 40%, low-certainty evidence). This suggests that if the chance of gastrointestinal discomfort following placebo or no treatment is assumed to be 2%, the chance following the use of antioxidants is estimated to be between 2% and 7%. However, this result was based on a low event rate of 46 out of 1355 men in 16 small or medium-sized studies, and the certainty of the evidence was rated low and heterogeneity was high. We were unable to draw conclusions from the antioxidant versus antioxidant comparison as insufficient studies compared the same interventions.<h4>Authors' conclusions</h4>In this review, there is very low-certainty evidence from 12 small or medium-sized randomised controlled trials suggesting that antioxidant supplementation in subfertile males may improve live birth rates for couples attending fertility clinics. Low-certainty evidence suggests that clinical pregnancy rates may increase. There is no evidence of increased risk of miscarriage, however antioxidants may give more mild gastrointestinal discomfort, based on very low-certainty evidence. Subfertile couples should be advised that overall, the current evidence is inconclusive based on serious risk of bias due to poor reporting of methods of randomisation, failure to report on the clinical outcomes live birth rate and clinical pregnancy, often unclear or even high attrition, and also imprecision due to often low event rates and small overall sample sizes. Further large well-designed randomised placebo-controlled trials studying infertile men and reporting on pregnancy and live births are still required to clarify the exact role of antioxidants.
dc.format.medium Electronic
dc.language eng
dc.publisher Wiley
dc.relation.ispartofseries The Cochrane database of systematic reviews
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.
dc.rights This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2022, 5. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review.
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm
dc.rights.uri https://documentation.cochrane.org/display/EPPR/Standard+%7C+Cochrane+Review
dc.subject Humans
dc.subject Infertility, Male
dc.subject Infertility, Female
dc.subject Abortion, Spontaneous
dc.subject Antioxidants
dc.subject Pregnancy Rate
dc.subject Pregnancy
dc.subject Adolescent
dc.subject Adult
dc.subject Aged
dc.subject Middle Aged
dc.subject Child
dc.subject Female
dc.subject Male
dc.subject Live Birth
dc.subject Young Adult
dc.subject Contraception/Reproduction
dc.subject Prevention
dc.subject Infertility
dc.subject Clinical Research
dc.subject Clinical Trials and Supportive Activities
dc.subject 6.1 Pharmaceuticals
dc.subject Reproductive health and childbirth
dc.subject 11 Medical and Health Sciences
dc.subject 17 Psychology and Cognitive Sciences
dc.title Antioxidants for male subfertility.
dc.type Journal Article
dc.identifier.doi 10.1002/14651858.cd007411.pub5
pubs.issue 5
pubs.begin-page CD007411
pubs.volume 5
dc.date.updated 2022-05-16T02:23:00Z
dc.rights.holder Copyright: The Cochrane Collaboration en
dc.identifier.pmid 35506389 (pubmed)
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/35506389
pubs.publication-status Published
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype Review
pubs.subtype Journal Article
pubs.elements-id 900352
pubs.org-id Medical and Health Sciences
pubs.org-id School of Medicine
pubs.org-id Obstetrics and Gynaecology
dc.identifier.eissn 1469-493X
pubs.record-created-at-source-date 2022-05-16
pubs.online-publication-date 2022-05-04


Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics